Talis Biomedical Co. (NASDAQ:TLIS – Get Rating)’s share price dropped 1.8% during trading on Thursday . The stock traded as low as $0.52 and last traded at $0.53. Approximately 137,153 shares traded hands during trading, a decline of 22% from the average daily volume of 176,019 shares. The stock had previously closed at $0.54.
Talis Biomedical Trading Down 1.8 %
The firm has a 50-day moving average of $0.52 and a 200 day moving average of $0.70.
Talis Biomedical (NASDAQ:TLIS – Get Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.24). The firm had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.20 million. Talis Biomedical had a negative return on equity of 59.90% and a negative net margin of 2,119.66%. As a group, research analysts predict that Talis Biomedical Co. will post -4.03 EPS for the current fiscal year.
Institutional Inflows and Outflows
Talis Biomedical Company Profile
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19.
- Get a free copy of the StockNews.com research report on Talis Biomedical (TLIS)
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy’s Stock Uptrend Set To Continue?
Receive News & Ratings for Talis Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talis Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.